We aim to use AI to cut down drug innovation time by 30%: Bayer Pharmaceuticals (www.cnbc.com)

Bayer Pharmaceuticals has announced its ambitious goal to leverage AI technology to reduce the time required for drug innovation by 30%. COO Sebastien Guth emphasizes the critical role of AI across the company's operations, highlighting its potential to streamline research and development processes. This initiative aligns with Bayer's broader strategy to enhance efficiency and responsiveness in bringing new therapies to market amid growing global health challenges. The significance of this development for the AI/ML community lies in Bayer's commitment to integrating advanced technologies within the highly regulated pharmaceutical sector. By aiming to cut drug development timelines substantially, Bayer could potentially accelerate the delivery of life-saving medications to patients. Additionally, as the company seeks simultaneous regulatory approvals in China and the U.S., the integration of AI may also pave the way for improved collaboration and innovation across international markets, making this a pivotal moment in the intersection of pharmaceuticals and artificial intelligence.